Publications

Explore a selection of Dr. Xue’s publications below.

  1. Ruan J, Liang D, Yan W, Zhong Y, Talley DC, Rai G, Tao D, LeClair CA, Simeonov A, Zhang Y, Chen F, Quinney NL, Boyles SE, Cholon DM, Gentzsch M, Henderson MJ, Xue F, Fang S. 2022. A small-molecule inhibitor and degrader of the RNF5 ubiquitin ligase. Mol. Biol. Cell 33(3):ar120. PMID: 36074076
  2. Zhang J, Li Q, Kawashima SA, Nasr M, Xue F, Zhao R. 2022. Improving drug sensitivity of HIV-1 protease inhibitors by restriction of cellular efflux system in a fission yeast model. Pathogen 11(7):804. PMID: 35890048
  3. Stern S, Liang D, Li L, Kurian R, Lynch C, Srilatha S, Heyward S, Zhang J, Kareen KA, Chun Y W, Huang R, Xia M, Charles C, Xue F, Wang H. 2022. Targeting CAR-Nrf2 improves cyclophosphamide bioactivation while reducing doxorubicin-induced cardiotoxicity in triple-negative breast cancer treatment.  JCI Insight 7(12):e153868. PMID: 35579950
  4. Ai Y, Sakamuru S, Imler G, Xia M, Xue F. 2022. Wnt/β-catenin signaling inhibitors with improved aqueous solubility and anti-leukemia activity by disrupting molecular planarity.  Bioorg. Med. Chem. 69:116890. PMID: 35777269
  5. Frank A, Hamidi N, Xue F. 2022.  Regioselective alkylation of 2,4-dihydroxybenzyaldehyde and 2,4-dihydroxyacetophenones.  Tetrahedron Lett. 95:153755. PMID: 35495552
  6. Robinson E, Frankenberg-Dinkel N, Xue F, Wilks A. 2021. Recombinant production of biliverdin IXb and d isomers in the T7 promoter compatible Escherichia coli Nissle (EcN(T7)). Front. Microbiol. 12:787609. PMID: 34956154
  7. Ai Y, Hwang L, MacKerell Jr. AD, Melnick A, Xue F. 2021. Progress towards B-cell lymphoma 6 BTB domain inhibitors for the treatment of diffuse large B-cell lymphoma and beyond. J. Med. Chem. 64(8):4333-4358.  PMID: 33844535
  8. Robinson E, Wilks A, Xue F. 2021. Repurposing acitretin as an antipseudomonal agent targeting the Pseudomonas aeruginosa iron-regulated heme oxygenase. Biochemistry 60(9):689-698. PMID: 33621054
  9. Diethelm-Varela B, Kumar A, Lynch C, Imler G, Deschamps J, Li Y, Xia M, MacKerell Jr., AD, Xue F. 2021. Stereoisomerization of 6-(4-chlorophenyl)imidazo[2,1-b][1,3]thiazole-5-carbaldehyde-O-(3,4-dichlorobenzyl)oxime (CITCO). Tetrahedron, 79: 131886. (Cover Article)
  10. Centola G, Deredge DJ, Hom K, Dent AT, Xue F, Wilks A. 2020. Gallium (III) salophen as a dual inhibitor of Pseudomonas aeruginosa heme sensing and iron acquisition. ACS Infect. Dis. 6(8): 2073-2085.  PMCID: 32551497
  11. Thomas JM, Wang X, Gong G, Li T, Dai B, Sun X, Nucifora LG, Nucifora Jr. FC, Liu Z, Xue F, Liu C, Ross CA, Smith W. 2020. GTP-binding inhibitors increase LRRK2-linked ubiquitination and inclusions. J. Cell. Physiol. in press.
  12. Cai Y, Watkins MA, Xue F, Ai Y, Cheng HM, Midkiff CC, Wang X, Alvarez X, Salvino JM, Veazey RS, Montaner L. 2020. BCL6 BTB-specific Inhibition via FX1 Treatment Reduces Tfh Cells & Reverses Lymphoid Follicle Hyperplasia in Indian Rhesus Macaque (Macaca mulatta). J. Med. Primatol. 49(1):26-33. PMID: 31571234.
  13. Yang, W.; Li, Y.; Ai, Y.; Obianom, O. N.; Guo, D.; Yang, H.; Sakamuru, S.; Xia, M.; Shu, Y.; Xue, F. 2019. “Pyrazole-4-Carboxamide (YW2065): A Therapeutic Candidate for Colorectal Cancer via Dual Activities of Wnt/β-Catenin Signaling Inhibition and AMP-Activated Protein Kinase (AMPK) Activation” J. Med. Chem. 62(24):11151-11164. PMID: 31769984.
  14. Liang, D.; Li, L.; Lynch, C.; Xia, M.; Wang, H.; Xue, F. 2019. DL5050: a selective agonist for the human constitutive androstane receptor. ACS Med. Chem. Lett. 10(7):1039-1044. PMID: 31312405.
  15. Liang D, Li L, Lynch C, Mackowiak B, Hedrich WD, Ai Y, Yin Y, Heyward S, Xia M, Wang H, Xue F. 2019. Human constitutive androstane receptor agonist DL5016: a novel sensitizer for cyclophosphamide-based chemotherapies.  Eur. J. Med. Chem. 179:84-99. PMID: 31247375.
  16. Diethelm-Varela, B.; Ai, Y.; Liang, D.; Xue, F. 2019. Nitrogen mustards as anticancer chemotherapies: historic perspective, current developments, and future trends. Curr. Topics Med. Chem. 19(9): 691-712.
  17. Zhao, J.; Liang, D.; Robinson, E.; Xue, F. 2019. The effects of novel heme oxygenase inhibitors on the growth of Pseudomonas aeruginosa. Microb. Pathog. 129:64-67. PMCID: 30716393.
  18. Obianom ON, Ai Y, Li Y, Yang W, Guo D, Yang H, Sakamuru S, Xia M, Xue F, Shu Y. 2019. Triazole-Based Inhibitors of the Wnt/β-Catenin Signaling Pathway Improves Glucose and Lipid Metabolism in Diet-Induced Obese Mice. J. Med. Chem. 62:721-741. PMCID: 30605343.
  19. Ai, Y.; Obianom, O. N.; Kuser, M.; Li, Y.; Shu, Y.; Xue, F. 2019. Enhanced Tumor-Selectivity of 5-Fluorouracil using a Reactive Oxygen Species-Activated Prodrug Approach. ACS Med. Chem. Lett. 10:127-131. PMID: 30655959.
  20. Cai, Y.; Abdel-Mohsen, M.; Tomescu, C.; Xue, F.; Wu, G.; Howell, B. J.; Ai, Y.; Sun, J.; Azzoni, L.; Coz, C. L.; Romberg, N.; Montaner, L. J. 2019. BCL6 Inhibitor-mediated Downregulation of pSAMHD1 and T Cell Activation Are Negatively Associated with HIV Infection and Reactivation. J. Virol. 93:e01073-18. PMID: 30355686.
  21. Metry, M.; Felton, J.; Cheng, K.; Xu, S.; Ai, Y.; Xue, F.; Raufman, J.; Polli, J. “Attenuated Accumulation of Novel Fluorine (19F)-Labeled Bile Acid Analogues in Gallbladders of Fibroblast Growth Factor-15 (FGF15)-Deficient Mice” Mol. Pharm. 2018, 15, 4827-4834.
  22. Heinzl, G. A.; Huang, W.; Xue, F.; Moenne-Loccoz, P.; Wilks, A. “The Asp99-Arg188 Salt Bridge of the Pseudomonas aeruginosa HemO is Critical in Allowing Conformational Flexibility During” J. Biol. Inorg. Chem. 2018, 23, 1057-1070.
  23. Cheng, H.; Linhares, B. M.; Yu, W.; Cardenas, M. G.; Ai, Y.; Jiang, W.; Melnick, A.; MacKerell, A.; Cierpicki, T.; Xue, F.* “Thiourea-Based Inhibitors of the BCL6 BTB Domain via NMR-Based Fragment Screening and Computer-Aided Drug Design” J. Med. Chem. 2018, 61, 7573-7588.
  24. Liang, D.; Robinson, E.; Hom, K.; Yu, W.; Nguyen, N.; Li, Y.; Zong, Q.; Wilks, A. Xue, F.* “Structure-based design and biological evaluation of inhibitors of the Pseudomonas aeruginosa heme oxygenase (pa-HemO)” Bioorg. Med. Chem. Lett. 2018, 28, 1024-1029.
  25. Gao, Y.; Zhu, W.; Yin, L.; Dong, B.; Fu, J.; Ye, Z.; Jiang, C.; Xue, F.* “Palladim-Catalyzed Direct C2-Arylation of Free (N-H) Indoles via Norbornene-Mediated Regioselective C-H Activation” Tetrahedron Lett. 2017, 58, 2213-2216.
  26. Liang, D.; Sersen, D.; Deschamps, J. R.; Imler, G. H.; Chao, J.; Xue, F.* “One-Pot Sequential Reaction to 2-Substituted-Phenanthridinones from N–Methoxybenzamides” Org. Biomol. Chem. 2017, 15, 4390-4398.
  27. Deb, D.; Rajaram, S.; Larsen, J. E.; Dospoy, P. P.; Marullo, R.; Li, L. S.; Avila, K.; Xue, F.; Cerchietti, L.; Minna, J. D.; Altschuler, S. J.; Wu, L. F. “A Novel Combination Therapy Targeting BCL6 and Phospho-STAT3 Defeats Intra-tumor Heterogeneity in a Subset of Non-Small Cell Lung Cancer” Cancer Res. 2017, 77, 3070-3081.
  28. Liang, D.; Yu, W.; Nguyen, N.; Deschamps, J. R.; Imler, G. H.; Li, Y.; MacKerell, Jr., A. D.; Xue, F.* “Iodobenzene-Catalyzed Synthesis of Phenanthridiones via Oxidative C-H Amidation” J. Org. Chem. 2017, 82, 3589-3596.
  29. Obianom, O. N.; Coutinho, A. L.; Yang, W.; Yang, H.; Xue, F.*; Shu, Y. “Incorporation of a Biguanide Scaffold Enhances Drug Uptake by Organic Cation Transporter 1 and 2” Mol. Pharm. 2017, 14, 2726-2739.
  30. Madapura, H. S.; Nagy, N.; Njvari, D.; Kallas, T.; Krohnke, M.; Amu, S.; Bjorkholm, M.; Stenke, L.; Mandal, P. K.; McMurray, J. S.; Keszei, M.; Westerberg, L. S.; Cheng, H.; Xue, F.; Klein, G.; Klein, E.; Salamon, D. “Interferon γ is a STAT1-Dependent Direct Inducer of BCL6 Expression in Imatinib Treated Chronic Myeloid Leukemia Cells” Oncogene, 2017, 1-10.
  31. Thomas, J. M.; Li, T.; Yang, W.; Xue, F.; Fishman, P. S.; Smith, W. “68 and FX2149 attenuate mutant LRRK2-R1441C-induced neural transport impairment” Front. Aging Neurosci., 2017, 8, Article 337(1-11)..
  32. Cardenas M. G.; Yu, Xue, F.; MacKerell, A. D.; Melnick, M. M. “Therapeutic Targeting of GCB- and ABC-DLBCLs by Rationally Designed BCL6 Inhibitors” Clin. Cancer Res. 2017, 23, 885-893.
  33. Yang, C.; Cheng, G.; Huang, B.; Xue, F.*; Jiang, C. “Metal-free Regioselective Construction of Indolin-3-ones via Hypervalent Iodine Oxidation of N-Substituted Indoles” RSC Adv. 2016, 6, 87134-87141.
  34. Heinzl, G. A.; Huang, W.; Yu, W.; Giardina, B. J.; Zhou, Y.; MacKerell, A. D.; Wilks, A.; Xue, F.* “Iminoguanidines as Allosteric Inhibitors of the Iron-Regulated Heme Oxygenase (HemO) of Pseudomonas aeruginosa” J. Med. Chem. 2016, 59, 6929-6942.
  35. Cardenas M. G.; Yu, Wendy Beguelin, W.; Teater, M. R.; Geng, H.; Goldstein, R. L.; Oswald, E.; Katerina Hatzi1, K.; Yang, S.; Cohen, J.; Shaknovich, R.; Vanommeslaeghe, K.; Cheng, H.; Liang, D.; Cho, H. J.; Abbott, J.; Tam, W.; Leonard, J. P.; Cerchietti, L.; Cierpicki, T.; Xue, F.;*  MacKerell, A. D.; Melnick, M. M. “Therapeutic Targeting of GCB- and ABC-DLBCLs by Rationally Designed BCL6 Inhibitors” J. Clin. Invest. 2016, 126, 3351-3362 (cover article).
  36. Zhao, J.; Xue, F.*; Jiang, C. “Aminoquinoline-Assisted Vinylic C−H Arylation of Unsubstituted Acrylamide for the Selective Synthesis of Z Olefins” Org. Biomol. Chem. 2016, 14, 3298-3306.
  37. Yang, W.; Coutinho, A.; L.; Abdel-Hafez, A. A.; Jiang, C.; Xue, F. “Ligand-Free Copper-Mediated N-Arylation of Spirocyclic Keto-Lactams” Tetrahedron Lett. 2015, 55, 5599-5603.
  38. Zhao, J.; Chen. X.; Le, J.; Yang, W.; Xue, F.; Zhang, X.; Jiang, C. “Cu-Mediated Direct Regiose-lective C-2 Chlorination of Indoles” Org. Biomol. Chem. 2015, 13(34), 9000-9004.
  39. Holden, J. K.; Dejam, D.; Lewis M. C.; Huang, H.; Kang, S.; Jing, Q.; Xue, F.; Silverman, R. B.; Poulos, T. L. “Inhibitor Bound Crystal Structures of Bacterial Nitric Oxide Synthase” Biochemistry 2015, 54, 4075-4082.
  40. Yang, W.; Sun, X.; Yu, W.; Rai, R.; Deschamps, J. R.; Mitchell, L. A.; Jiang, C.; MacKerell, Jr., A. D.; Xue, F.* “Facile Synthesis of Spirocyclic Lactams from β-Keto Carboxylic Acids” Org. Lett. 2015, 17, 3070-3073.
  41. Lakkaraju, S. K.; Mbatia, H.; Hanscom, M.; Zhao, Z.; Wu, J.; Stoica, B.; MacKerell, Jr., A. D.; Faden, A. I.; Xue, F.* “Cyclopropyl-Containing Positive Allosteric Modulators of Metabotropic Glutamate Receptor Subtype 5” Bioorg. Med. Chem. Lett. 2015, 25, 2275-2279.
  42. He, X.; Lakkaraju, S. K.; Hanscom, M.; Zhao, Z.; Wu, J.; Stoica, B.; MacKerell, Jr., A. D.; Faden, A. I.; Xue, F. “Acyl-2-Aminobenzimidazoles: A Novel Class of Neuroprotective Agents Targeting mGluR5” Bioorg. Med. Chem. 2015, 23, 2211-2220.
  43. Li, T.; He. X.; Thomas, J. M.; Yang, D.; Zhong, S.; Xue, F.*; Smith, W. “A Novel GTP-Binding Inhibitor, FX2149, Attenuates LRRK2 Toxicity in Parkinson’s Disease Models” PlosOne 2015, 10: e0122461.
  44. He, X.; Aglio, T.; Deschamps, J. R.; Rai, R.; Xue, F.* “Synthesis of 1,2-Dihydro-2-Oxo-4-Quinolinyl Phosphates From 2-Acyl-Benzoic Acids” Tetrahedron Lett. 2015, 56, 1441-1444.
  45. He, X.; Kassab, S. E.; Heinzl, G.; Xue, F.* “Base-Catalyzed One-Step Synthesis of 5,7-Disubstituted-1,2,4-Triazolo[1,5-a]pyrimidines” Tetrahedron Lett. 2015, 56, 1034-1037.
  46. Holden, J.; Kang, S.; Hollingsworth, S.; Li, H.; Lim, N.; Chen, S.; Huang, H.; Xue, F.; Tang, W.; Silverman, R.; Poulos, T. “Structure-Based Design of Bacterial Nitric Oxide Synthase Inhibitors” J. Med. Chem. 2015, 58, 994-1004.
  47. Loane, D. J.; Stoica, B. A.; Tchantchou, F.; Kumar, A.; Barrett, J. P.; Akintola, T.; Xue, F.; Conn, P. J.; Faden, A. I. “Novel mGluR5 Positive Allosteric ModulatorImproves Functional Recovery, Attenuates Neurodegeneration,and Alters Microglial Polarization after Experimental TraumaticBrain Injury” Neurotherapeutics, 2014, 11, 857-869.
  48. Li, T.; Yang, D.; Zhong, S.; Thomas, J. M.; Xue, F.; Liu, J.; Kong, L.; Voulalas, P.; Hassan, H. E.; Park, J. S.; MacKerell, Jr., A. D.; Smith, W. W. “Novel LRRK2 GTP-binding Inhibitors Reduced Degeneration in Parkinson’s Disease Cell and Mouse Models” Hum. Mol. Genet. 2014, 23, 6212-6222.
  49. Sun, X.; Rai, R.; MacKerell, Jr., A. D.; Faden, A. I.; Xue, F.* “Facile One-Step Synthesis of 2,5-Diketopiperazines” Tetrahedron Lett. 2014, 55, 1905-1908.
  50. He, X.; Xue, F.* “Transition-Metal-Free Synthesis of (Z)-3-Ylidenephthalides from 2-Acyl-Benzoic Acids” Tetrahedron Lett. 2014, 55, 1956-1958.
  51. Xue, F.; Stoica, B. A.; Hanscom, M.; Kabadi, S. V.; Faden, A. I. “Positive Allosteric Modulators (PAMs) of Metabotropic Glutamate Receptor 5 (mGluR5) Attenuate Microglial Activation” CNS & Neurol. Disord. Drug Targets 2014, 13, 558-566.
  52. Kao, J. P. Y.; Muralidharan, S.; Zavalij, P. Y.; Fletcher, S.; Xue, F.; Rosen, G. M. “Baeyer-Villiger Rearrangement of a Substituted Pyrrole by Oxone” Tetrahedron Lett. 2014, 55, 3111-3113.
  53. Sun, X.; Rai, R.; Deschamps, J. R.; MacKerell, Jr., A. D.; Faden, A. I.; Xue, F.* “Boc-Protected 1-(3-Oxocycloalkyl)ureas via a One-Step Curtius Rearrangement: Mechanism and Scope”  Tetrahedron Lett. 2014, 55, 842-844.
  54. Hatzi, K.; Jiang, Y.; Huang, C.; Garrett-Bakelman, F.; Gearhart, M. D.; Giannopoulou, E. G.; Zumbo, P.; Kirouac, K.; Bhaskara, S.; Polo, J. M.; Kormaksson, M.; MacKerell, Jr., A. D.; Xue, F.; Mason, C. E.; Hiebert, S. W.; Prive, G. G.; Cerchietti, L.; Bardwell, V. J.; Elemento, O.; Melnick, A. “A Hybrid Mechanism of Action for BCL6 in B Cells Defined by Formation of Functionally Distinct Complexes at Enhancers and Promoter” Cell Reports, 2013, 4, 573-588.
  55. Lakkaraju, S. K.; Xue, F.; MacKerell, Jr., A. D. “Estimation of Ligand Efficacies of Metabotropic Glutamate Receptors from Conformational Forces Obtained from Molecular Dynamics Simulations” J. Chem. Info. Model. 2013, 53, 1337-1349.
  56. Hom, K.; Heinzl, G. A.; Suntara, E.; Pedro, L.; Xue, F.; MacKerell, Jr., A. D.; Wilks, A. “Small Molecule Antivirulents Targeting the Iron-Regulated Heme Oxygenase (HemO) of P. Aeruginsa” J. Med. Chem. 2013, 54, 1700-1703.
  57. Xue, F.*; Stoica, B. A.; Hanscom, M.; Kabadi, S. V.; Faden, A. I. “Positive Allosteric Modulators (PAMs) of Metabotropic Glutamate Receptor 5 (mGluR5) Attenuate Microglial Activation” CNS & Neurol. Disord. Drug Targets 2013, accepted.
  58. Shanthi, N.; Xue, F.; MacKerell, Jr., A. D. “Impact of Substrate Protonation and Tautomerization States on Interactions with the Active Site of Arginase I” J. Chem. Info. Model. 2013, 53, 452-460. (Cover Article)
  59. Xue, F.*; MacKerell, Jr., A. D.; Heinzl, G.; Hom, K. “Room Temperature Catalyst-Free Knoevenagel Condensation: Facile Access to Isatinylidenerhodanines” Tetrahedron Lett. 2013, 54, 1700-1703.
  60. Li, H.; Xue, F.; Kraus, J. M.; Ji, H.; Labby, K. J.; Mataka, J.; Delker, S. L.; Martasek, P.; Roman, L. J.; Poulos, T. L.; Silverman, R. B. “Cyclopropyl- and Methyl-Containing Inhibitors of Neuronal Nitric Oxide Synthase” Bioorg. Med. Chem. 2013, 21, 1333-1343.
  61. Labby, K. J.; Xue, F.; Kraus, J. M.; Ji, H.; Mataka, J.; Li, H.; Martasek, P.; Roman, L.; Poulos, T. L.; Silverman, R. B. “Intramolecular Hydrogen Bonding: A Potential Strategy for More Bioavailable Inhibitors of Neuronal Nitric Oxide Synthase ” Bioorg. Med. Chem. 2012, 20, 2435-2443.
  62. Xue, F.; Fraus, J.; Labby, K. J.; Li, H.; Ji, H.; Mataka, J.; Poulos, T. L.; Silverman, R. B. “Improved Synthesis of Chiral Pyrrolidine Inhibitors and Their Binding Properties to Neuronal Nitric Oxide Synthase.”  J. Med. Chem. 2011, 54, 6399-6403.
  63. Xue, F.; Delker, S. L.; Li, H.; Fang, J.; Jamal, J.; Silverman, R. B.; Poulos, T. L. “Symmetric Double-Headed Aminopyridines, A Novel Strategy for Potent and Membrane-Permeable Inhibitors of Neuronal Nitric Oxide Synthase.”  J. Med. Chem. 2011, 54, 2039-2048.
  64. Atia, A.; Fernand, G.-P.; Hébuterne, X.; Spies, W.; Guardiola, A.; Ahn, C.; Fryer, J.; Xue, F.; Englyst, K.; Buchman, A. L. “Pectin Supplementation Increases Colonic Short Chain Fatty Acid (SCFA) Production in Patients with Short Bowel Syndrome (SBS).”  JPEN, 2011, 35, 229-240.
  65. Xue, F.; Seto, C. T. “Kinetic Delay of Cyclization/Elimination-Coupled Enzyme Assays: Analysis and Solution.”  Bioorg. Med. Chem. Lett., 2011, 21, 1069-1071.
  66. Delker, S. L.; Xue, F.; Li, H.; Jamal, J.; Silverman, R. B.; Poulos, T. L. “The Role of Zinc in Isoform-Selective Inhibitors for Nitric Oxide Synthase.” Biochemistry, 2010, 49, 10803-10810 (highlighted on the homepage of Biochemistry).
  67. Xue, F.; Li, H.; Fang, J.; Poulos, T. L.; Silverman, R. B. “Potent, Highly Selective, and Orally Bioavailable Gem-Difluorinated Monocationic Inhibitors of Neuronal Nitric Oxide Synthase.”  J. Am. Chem. Soc. 2010, 132, 14229-14238.
  68. Xue, F.; Li, H.; Fang, J.; Poulos, T. L.; Silverman, R. B. “Peripheral but Crucial: the Hydrophobic Pocket (Tyr706, Leu337, and Met336) for Potent and Selective Inhibition of Neuronal Nitric Oxide Synthase.”  Bioorg. Med. Chem. Lett. 2010, 20, 6258-6261.
  69. Xue, F.; Huang, J.; Li, H.; J.; Ji, H.; Fang, J.; Poulos T, L.; Silverman, R. B. “Structure-Based Design, Synthesis, and Biological Evaluation of Lipophilic-Tailed Monocationic Inhibitors of Neuronal Nitric Oxide Synthase.”  Bioorg. Med. Chem. 2010, 18, 6526-6537.
  70. Xue, F.; Seto, C. T. “Fluorescent Probes to Study Serine/Threonine Phosphatase.”  Org. Lett. 2010, 12, 1936-1939.
  71. Delker, S. L.; Ji, H.; Li, H.; Jamal, J.; Fang, J.; Xue, F.; Silverman, R. B.; Poulos, T. L. “Unexpected Binding Modes of Nitric Oxide Synthase Inhibitors Effective in the Prevention of Cerebral Palsy.”  J. Am. Chem. Soc. 2010, 132, 5437-5442.
  72. Xue, F.; Silverman, R. B. “An Alkoxide Anion-triggered tert-Butyloxycarbonyl Group Migration.  Mechanism and Application.”  Tetrahedron Lett. 2010, 51, 2536-2538.
  73. Xue, F.; Fang, J.; Lewis, W. W.; Martasek, P.; Roman, L. J.; Silverman, R. B. “Potent and Selective Neuronal Nitric Oxide Synthase Inhibitors with Improved Cellular Permeability.”  Bioorg. Med. Chem. Lett. 2010, 20, 554-557.
  74. Xue, F.; Gu, W.; Silverman, R. B. “A Concise Route to the Chiral Pyrrolidine Core of Selective Inhibitors of Neuronal Nitric Oxide Synthase.”  Org. Lett. 2009, 11, 5194-5197.
  75. Fang, J.; Ji, H.; Lawton, G.; Xue, F.; Roman, L.; Silverman, R. B. “L337H Mutant of Rat Neuronal Nitric Oxide Synthase Resembles Human Neuronal Nitric Oxide Synthase Toward Inhibitors.”  J. Med. Chem. 2009, 52, 4533-4537.
  76. Xue, F.; Seto, C. T. “Macrocyclic Inhibitors of the Serine Protease Plasmin.”  J. Enzyme Inhib. Med. Chem. 2009, 24, 779-794.
  77. Lawton, G. R.; Ranaivo, H. R.; Wing, L. K.; Ji, H.; Xue, F.; Martesek, P.; Roman, L. J.; Watterson, D. M.; Silverman, R. B. “Analogues of 2-Aminopyridine-Based Selective Inhibitors of Neuronal Nitric Oxide Synthase with Increased Bioavailability.”  Bioorg. Med. Chem. 2009, 17, 2371-2380.
  78. Ji, H.; Erdal, E. P.; Litzinger, E. A.; Seo, J.; Zhu, Y.; Xue, F.; Fang, J.; Huang, J.; Silverman, R. B. “Selective Neuronal Nitric Oxide Synthase Inhibitors.”  Frontiers in Medicinal Chemistry, Reitz, A. B.; Choudhary, M. I.; Atta-ur-Rahman, Editors; Bentham Science Publishers, Volume 4, 2009, 842-882.
  79. Hassanein, M.; Xue, F.; Seto, C. T.; Mason, R. W. “Development of a Specific Inhibitor for the Placental Protease, Cathepsin P.”  Arch. Biochem. Biophys. 2007, 464, 288-294.
  80. Xue, F.; Seto, C. T. “Structure-Activity Studies of Inhibitors for the Serine Protease Plasmin: Design, Synthesis, and Biological Activity.”  Bioorg. Med. Chem. 2006, 14, 8467-8487.
  81. Fei, J.; Basu, A.; Xue, F.; Palmore, G. T. R. “Two Polymerizable Derivatives of 2,2’-Azino-bis(3-ethylbenzthiazoline-6-sulfonic acid).”  Org. Lett. 2006, 8, 3-6.
  82. Xue, F.; Seto, C. T. “A Comparison of Cyclohexanone and Tetrahydro-4H-thiopyran-4-one 1,1-dioxide as Pharmacophores for the Design of Peptide-Based Inhibitors of the Serine Protease Plasmin.”  J. Org. Chem. 2005, 70, 8309-8321.
  83. Xue, F.; Seto, C. T. “Selective Inhibitors of the Serine Protease Plasmin:  Probing the S3 and S3’ Subsites Using a Combinatorial Library.”  J. Med. Chem. 2005, 68, 6908-6817.